Inhibitor 1 of Protein Phosphatase 1 Regulates Ca2+/Calmodulin-Dependent Protein Kinase II to Alleviate Oxidative Stress in Hypoxia-Reoxygenation Injury of Cardiomyocytes

Oxid Med Cell Longev. 2019 Dec 7:2019:2193019. doi: 10.1155/2019/2193019. eCollection 2019.

Abstract

Ca2+/calmodulin-dependent protein kinase II (CaMKII), regulated by inhibitor 1 of protein phosphatase 1 (I1PP1), is vital for maintaining cardiovascular homeostasis. However, the role and mechanism of I1PP1 against hypoxia-reoxygenation (H/R) injury in cardiomyocytes remain a question. In our study, after I1PP1 overexpression by adenovirus infection in the neonatal cardiomyocytes followed by hypoxia for 4 h and reoxygenation for 12 h, the CaMKIIδ alternative splicing subtype, ATP content, and lactate dehydrogenase (LDH) release were determined. CaMKII activity was evaluated by phosphoprotein phosphorylation at Thr17 (p-PLB Thr17), CaMKII phosphorylation (p-CaMKII), and CaMKII oxidation (ox-CaMKII). Reactive oxygen species (ROS), mitochondrial membrane potential, dynamin-related protein 1 (DRP1), and optic atrophy 1 (OPA1) expressions were assessed. Our study verified that I1PP1 overexpression attenuated the CaMKIIδ alternative splicing disorder; suppressed PLB phosphorylation at Thr17, p-CaMKII, and ox-CaMKII; decreased cell LDH release; increased ATP content; attenuated ROS production; increased mitochondrial membrane potential; and decreased DRP1 expression but increased OPA1 expression in the cardiomyocytes after H/R. Contrarily, CaMKIIδ alternative splicing disorder, LDH release, ATP reduction, and ROS accumulation were aggravated after H/R injury with the I1PP1 knockdown. Collectively, I1PP1 overexpression corrected disorders of CaMKIIδ alternative splicing, inhibited CaMKII phosphorylation, repressed CaMKII oxidation, suppressed ROS production, and attenuated cardiomyocyte H/R injury.

MeSH terms

  • Alternative Splicing
  • Animals
  • Benzylamines / pharmacology
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 / antagonists & inhibitors
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 / biosynthesis
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 / metabolism*
  • Cell Hypoxia / physiology*
  • Cells, Cultured
  • Dynamins / biosynthesis
  • GTP Phosphohydrolases / biosynthesis
  • Membrane Potential, Mitochondrial
  • Mitochondria / enzymology
  • Mitochondria / metabolism
  • Myocardial Reperfusion Injury / enzymology*
  • Myocardial Reperfusion Injury / metabolism
  • Myocardial Reperfusion Injury / pathology
  • Myocytes, Cardiac / enzymology*
  • Myocytes, Cardiac / metabolism
  • Myocytes, Cardiac / pathology
  • Oxidation-Reduction
  • Oxidative Stress / physiology*
  • Phosphorylation
  • Protein Kinase Inhibitors / pharmacology
  • Protein Phosphatase 1 / biosynthesis
  • Protein Phosphatase 1 / genetics
  • Protein Phosphatase 1 / metabolism*
  • Rats
  • Rats, Sprague-Dawley
  • Reactive Oxygen Species / metabolism
  • Sulfonamides / pharmacology

Substances

  • Benzylamines
  • Protein Kinase Inhibitors
  • Reactive Oxygen Species
  • Sulfonamides
  • KN 93
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2
  • Camk2d protein, rat
  • Protein Phosphatase 1
  • GTP Phosphohydrolases
  • Opa1 protein, rat
  • Dnm1l protein, rat
  • Dynamins